Regeneron - Eylea’s Growth Potential and Pipeline is Lucrative Enough!
Regeneron’s (REGN) growth trajectory will be sustained by the sales and upcoming label expansion of Eylea (aflibercept, VEGF-Trap Eye, L, wet-AMD, Central Retinal Vein Occlusion – CRVO, partnered with Bayer for ex-US) in Diabetic Macular Edema (DME) and myopic choroidal neovascularization (mCNV) and promise of the late-stage pipeline esp. anti-PCSK9 mAb, Alirocumab (REGN727, PhIII, Hypercholesterolemia, partnered with Sanofi). Not undermining the future potential of ... For more detail, please read our report released on Oct. 9, 2013 on REGN, titled, "Eylea’s Growth Potential and Pipeline is Lucrative Enough!"
